DataMeds AI, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MEDS in the last 30 days.
See all $MEDS insider activity →DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 11, 2026, DataMEDS AI, Inc. (the “Company”) entered into a settlement agreement and release (the “Agreement”) with Brian Norton, individually and as Seller Representative (“Norton”), Tony Madsen, Mark DiSiena, T. Scott Madsen, Stephen J. Madse
Axe Compute Inc. (AGPU) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Axe Compute Sells Helomics AI Cancer Diagnostics Lab Business to DataMEDS AI, Completing Transition to Neocloud GPU-as-a-Service platform September 15, 2026 All-stock sale gives Axe Compute equity stake in DataMEDS AI; aligns APU’s operating structure with its scalin
DataMEDS AI (MEDS) rose 295.53% after acquiring Helomics for $1.5M, expanding into precision oncology. Tempest Therapeutics (TPST) gained 58.86% with a CAR-T licensing deal. NeurAxis (NRXS) increased 22.63% on expanded insurance coverage for its PENFS therapy. MAIA Biotechnology (MAIA) rose 5.22% after dosing the first U.S. patient in its THIO-101 trial.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning MEDS (DataMeds AI, Inc.). Coverage has skewed bullish: 7 bullish, 0 neutral, and 0 bearish.
Recent MEDS coverage spans corporate actions, mergers & acquisitions and financial news.
Settlement reduces balance‑sheet liability and may improve credit metrics.
MEDS expands into oncology AI, adding a new revenue stream and increasing its data‑health platform scope.
Acquisition adds CLIA/CAP lab and cash, likely boosting revenue potential.
The deal expands DataMeds' service offering into cancer diagnostics, potentially boosting revenue streams.
Potential upside from entry into oncology diagnostics; short-term dilution risk from share issuance.
AlphAI scores every news story that mentions MEDS with an AI model for sentiment and relevance, and aggregates insider trades from DataMeds AI, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 11, 2026, DataMEDS AI, Inc. (the “Company”) entered into a settlement agreement and release (the “Agreement”) with Brian Norton, individually and as Seller Representative (“Norton”), Tony Madsen, Mark DiSiena, T. Scott Madsen, Stephen J. Madse
2 min readAxe Compute Inc. (AGPU) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Axe Compute Sells Helomics AI Cancer Diagnostics Lab Business to DataMEDS AI, Completing Transition to Neocloud GPU-as-a-Service platform September 15, 2026 All-stock sale gives Axe Compute equity stake in DataMEDS AI; aligns APU’s operating structure with its scalin
2 min readDataMEDS AI (MEDS) rose 295.53% after acquiring Helomics for $1.5M, expanding into precision oncology. Tempest Therapeutics (TPST) gained 58.86% with a CAR-T licensing deal. NeurAxis (NRXS) increased 22.63% on expanded insurance coverage for its PENFS therapy. MAIA Biotechnology (MAIA) rose 5.22% after dosing the first U.S. patient in its THIO-101 trial.
3 min readDataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 PRESS RELEASE DATAMEDS AI, INC. 3000 BAYPORT DRIVE, SUITE 950 TAMPA, FLA. 33607 WEBSITE RUBENSTEIN PUBLIC RELATIONS CONTACT: JAMES LAMBERT 212-805-3024 JLAMBERT@RUBENSTEINPR.COM FOR IMMEDIATE RELEASE DATAMEDS, AI. ACQUIRES HELOMICS AI CANCER DIAGNOSTICS LAB AND PRECI
2 min readDataMEDS AI, Inc. (NASDAQ:MEDS) acquired Helomics, an AI cancer diagnostics lab, from Axe Compute (NASDAQ:AGPU) for $1.5 million in shares and notes. The deal includes a CLIA/CAP-certified lab and a precision oncology CRO business. DataMEDS plans to expand into cancer management, while Axe Compute focuses on AI infrastructure. The transaction has no third-party debt.
2 min readDataMeds AI (NASDAQ:MEDS) and Tollo Health launched Galectovid, a medical food for viral infections, at 50% off for the 2026 Cold & Flu Season. Available online at TolloHealth.Shop and CorexaRx.com, Galectovid targets galectin-1 and galectin-3 proteins. The company expects consumer satisfaction and plans to expand research through physician relationships.
1 min readDataMeds AI (NASDAQ: MEDS) launched Galectovid, a medical food for viral infections, at 50% off during its #Back2School50% campaign. The product is available OTC via Tollo Health and Corexa Pharmacy. Galectovid targets galectin-1 and galectin-3 proteins and is classified as a medical food with GRAS-listed ingredients.
2 min readDataMeds AI (MEDS) and Datavault AI (DVLT) expanded their tech licensing deal, allowing Datavault's data monetization tech in DataMeds' healthcare apps. Datavault will receive 19.9% of DataMeds' common stock. The deal targets the growing healthcare data market, with DataMeds launching its 'Health Lives Here' app in 2026. DataMeds also rebranded and started trading under the new ticker 'MEDS'.
2 min readDataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update ■ Health Lives Here app launch with NFL Alumni Health expected in September 2026 ■ Revenues grew 14% reaching $1.779M in Q2/26, beating management projections ■ Corporate name change from
6 min readDataMeds AI, Inc. (NASDAQ:MEDS) said its board set Sept. 9, 2026 as the payment date for a previously announced distribution of Dream Bowl Meme Coin I tokens to record holders as of Aug. 7, 2026. Holders will receive 50 tokens per share. The company plans to distribute about 153,631,650 tokens and list them on Biconomy in Q3 2026.
4 min read
